Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 20/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669495 | 1.00 | MCHR1 (1.00) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5258406 | 0.96 | MCHR1 (0.92) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5256418 | 0.95 | MCHR1 (0.91) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5259118 | 0.92 | MCHR1 (1.00) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5260769 | 0.92 | MCHR1 (1.00) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5256326 | 0.92 | MCHR1 (1.00) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5255718 | 0.90 | MCHR1 (0.82) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL13738209 | 0.89 | MCHR1 (0.80) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5259428 | 0.89 | MCHR1 (0.80) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL14370191 | 0.89 | MCHR1 (0.80) | MCHR1CHRM4CYP3A4CHRM5ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250346646-A1 | COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-13 | — | — | US | disclosed |
| EP-2958562-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-120091810-A | Methods and highly bioavailable permeable compounds for treating viral diseases | 基里尔·迪丹克 | 2025-06-03 | — | — | CN | disclosed |
| WO-2024155618-A1 | COMPOSITIONS AND METHODS FOR TREATING WEIGHT GAIN AND/OR DISORDERS ASSOCIATED WITH ABNORMAL DE NOVO LIPOGENESIS, AND FAT ACCUMULATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-07-25 | — | — | WO | disclosed |
| EP-3436003-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220411490-A1 | METHOD TO IDENTIFY COMPOUNDS USEFUL TO TREAT DYSREGULATED LIPOGENESIS, DIABETES, AND RELATED DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-12-29 | — | — | US | disclosed |
| CN-109642908-B | Compounds useful for treating metabolic disorders | 哈佛学院院长及董事 | 2022-08-16 | — | — | CN | disclosed |
| US-11345748-B2 | Method of treating idiopathic pulmonary fibrosis and kidney fibrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345748-B2 | Method of treating idiopathic pulmonary fibrosis and kidney fibrosis | CNR2, FABP1, FABP4 | MCHR1 1809/4885CHRM4 2528/4885CYP3A4 3449/4885 |
| US-20220411490-A1 | METHOD TO IDENTIFY COMPOUNDS USEFUL TO TREAT DYSREGULATED LIPOGENESIS, DIABETES, AND RELATED DISORDERS | FABP4, LIPC, CNR2 | MCHR1 1571/4885CHRM4 3843/4885CYP3A4 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.